$PRVA

Mountcastle David sold $17K of PRVA

Mountcastle David (EVP & Chief Financial Officer) sold 600 shares of Privia Health Group, Inc. (PRVA) at $27.57 on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mountcastle David
Published Jul 9, 2026, 8:37 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PRVA
Neutral
high confidence
Mentioned
$PRVA
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRVANeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operational or financial catalysts.

02

Market read

Routine officer selling under a pre-arranged 10b5-1 plan, with limited expected impact on valuation.

03

What to watch

Traders may check whether the sale size is part of a larger scheduled program, but this brief only discloses the single transaction.

Relevance 2/10Novelty 2/10Timing: Filed 2026-07-09 after-hours; reflects a 2026-07-07 sale.

Background

This is an SEC Form 4 insider transaction for Privia Health Group, Inc., reported by the CFO.

Company-level read

Ticker impact

$PRVANeutralHigh confidence
Context

Privia CFO David Mountcastle sold 600 shares in an open-market transaction at $27.57 on 2026-07-07 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is a small, pre-arranged 10b5-1 open-market sale by an officer, with no accompanying guidance, deal, or regulatory event disclosed.

Market effects

No clear read-across to healthcare services or managed care; this is company-specific insider activity.

None.

None.

Counterpoint

Even 10b5-1 sales can coincide with private information, but the article provides no new qualitative context beyond the pre-arranged plan.

Key entities

  • Privia Health Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • David Mountcastle

    EVP and Chief Financial Officer who sold shares under a 10b5-1 plan.

Related articles

$PRVAHighAI 9/10

Privia Health Group, Inc. (PRVA): Results of Operations and Financial Condition

Privia Health Group, Inc. (PRVA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-9912q26earningrelease.htm EX-99.1 Document Exhibit 99.1 Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results – 2Q’26 Net Income of $9.0M, +236.7% from 2Q’25 – 2Q’26 Adjusted EBITDA of $37.4M, +29.1% from 2Q’25 – Full-Year 2026 Guidance Raised for